Analyse
Fundierte Analysen zu Pharmamärkten, Lieferketten, Technologie und Regulierung
#Korean pharma ×
Analyse
13. Sept. 2026•1 Min. Lesezeit
Celltrion Pharm’s Bio and CMO Sales Surpass Chemical Segment, Reaching 54% in H1
Celltrion Pharm’s bio‑pharma and contract‑manufacturing sales now exceed half of total revenue, narrowing the gap with its traditional chemical drugs.
Analyse
1. Sept. 2026•1 Min. Lesezeit
ST Pharm projected Q2 earnings beat expectations on oligonucleotide sales
ST Pharm is forecast to post Q2 revenue of 103.4 billion KRW and operating profit of 20.8 billion KRW, up 51.5% and 60.8% YoY, driven by oligonucleotide shipments and new orders.
Analyse
31. Aug. 2026•1 Min. Lesezeit
Hanmi Pharm Q2 earnings buoyed by one‑off Lilly tech transfer payment, core sales lag
Hanmi Pharm's Q2 results show strong growth due to a KRW 112.9 bn upfront from Eli Lilly for GLP‑2 candidate sonepegLutide, but analysts say core sales remain weak.
Analyse
30. Aug. 2026•1 Min. Lesezeit
WiseBuzz Forms US DTC Advertising Team to Support Korean Pharma Expansion
WiseBuzz announced the creation of a dedicated US Direct‑to‑Consumer advertising team to help Korean pharma and biotech firms launch DTC campaigns in the United States.
Analyse
30. Aug. 2026•1 Min. Lesezeit
Supply Prices of Hydrasexan Antidiarrheal Raised Effective July 1
Korean Aebot and Samjin Pharma have sharply increased the supply price of the pediatric and adult antidiarrheal Hydrasexan due to raw‑material costs and exchange‑rate shifts.